A Phase 2 interventional study of SRP-001 and Matching Placebo for SRP-001 in Acute Pain, Postoperative Pain and Pain, sponsored by South Rampart Pharma, Inc.. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by South Rampart Pharma, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 353 studies in Acute Pain with a site in United States — 49 open to participants now, 55 under way, 1 of them phase 3. Acute Pain · United States.
Among the 353 studies in Acute Pain with a site in United States, this one is the 112th largest by planned enrollment of the 322 interventional ones that give a count, is one of 14 that started in 2026, is one of 56 in phase 2, reaches primary completion later than 23 of the 54 other live ones, and was the 352nd registered.
1,076 studies on the registry are indexed under Acute Pain; 168 are open to participants now.
Browse Acute Pain studies →49 of the 353 studies in Acute Pain with a site in United States are open now. Recruiting first, the newest first:
Duke University · Sites in United States
Ages 18+ · Healthy volunteers
Aponia Laboratories, Inc. · Sites in United States, Germany
Ages 18–65
Florida State University · Sites in United States
Ages 18+
Eli Lilly and Company · Sites in United States
Ages 18–40
Ochsner Health System · Sites in United States
Ages 35+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 103 Acute Pain studies recruiting now, 40 (39%) set no upper age limit and 50 (49%) stop at 75 or younger; 21 take children under 18; 24 take healthy volunteers.
This study: 18 Years to 50 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
353 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 30 · Phase 2 65 · Phase 3 48 · Phase 4 66
First in 2001; this study’s year is marked. 14 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 130 is above the median of 86 across 904 interventional studies indexed under Acute Pain.
Median enrollment 86 across the 322 interventional studies, 100 across the 31 observational. Of the 265 that completed or were terminated, 133 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
79 of 353 have an industry lead sponsor. The 10 most frequent:
South Rampart Pharma, Inc. is the lead sponsor of 2 studies on the registry; 1 is open to participants now.
South Rampart Pharma, Inc. has 1 study filed under Acute Pain — fewer than ten, so there is no comparison to draw.
32 of the studies in Acute Pain with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07930559Phase 3Aponia Laboratories, Inc.Effect of S-Ibuprofen Gel on Pain in Acute Soft Tissue Contusions | 2027-06 |
| NCT07511816Eli Lilly and CompanyA Study of LY4515100 in Participants With Pain Following Third Molar Removal | 2026-11 |
| NCT05335070Rutgers, The State University of New JerseyReducing Pain From Wisdom Molar Extractions | 2026-11 |
| NCT06795126Nationwide Children's HospitalLittle NIRVANA for Pediatric Pain and Anxiety | 2026-11-30 |
| NCT05458037Women and Infants Hospital of Rhode IslandRCT of Pain Perception With Fast and Slow Tenaculum Application | 2026-12 |
Add all 32 to your calendar (.ics) → With an account.
Among the 353 studies in Acute Pain with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study tests whether a single oral dose of SRP-001 (2,000 mg), a non-opioid drug, relieves moderate-to-severe pain after surgery to remove impacted third molars (wisdom teeth), compared with placebo. It also evaluates safety and how the body processes the drug.
This is a single-center, randomized, double-blind, placebo-controlled, parallel-group Phase 2 study evaluating the analgesic efficacy, onset of action, pharmacokinetics, and safety of a single oral dose of SRP-001 (2,000 mg oral suspension) compared to matching placebo in 130 adult participants experiencing moderate-to-severe acute postoperative pain (NPRS ≥ 5 and categorical pain ≥ 2 within 4.5 hours) following extraction of two or more third molars (including at least two bone-impacted mandibular molars). Participants remain in the clinical research unit for 12 hours post-dose for serial efficacy, double-stopwatch onset, safety, and pharmacokinetic assessments, followed by 24-hour rescue diary tracking (two-tiered rescue: ibuprofen 400 mg, then oxycodone 5 mg if needed) and an in-person safety follow-up visit on Day 8 (± 2 days).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
SRP-001 Single Oral Suspension dose of 2,000 mg
Drug: SRP-001
Matching Placebo for SRP-001 Oral Suspension
Drug: Matching Placebo for SRP-001
SRP-001 Oral Suspension
Matching Placebo for SRP-001 Oral Suspension
Also known as: Control
Sum of Pain Intensity Differences Over 0 to 6 Hours (SPID0-6)
Time-weighted sum of pain intensity differences from baseline over 0 to 6 hours post-dose, assessed using the 0-10 Numeric Pain Rating Scale (NPRS scale 0 -10 higher being worse) comparing SRP-001 (2,000 mg) to placebo.
Time frame: 0 to 6 hours post-dose
Time-Weighted Sum of Pain Intensity Differences Over 0 to 2, 0 to 4, and 0 to 8 Hours (SPID0-2, SPID0-4, SPID0-8)
Time-weighted sum of pain intensity differences from baseline over 0 to 2 hours, 0 to 4 hours, and 0 to 8 hours post-dose assessed on the 0-10 NPRS (higher being worse)
Time frame: 0 to 2 hours, 0 to 4 hours, and 0 to 8 hours post-dose
Sum of pain relief (TOTPAR)
Sum of pain relief (TOTPAR) from 0 to 2 (TOTPAR0-2), 0 to 4 (TOTPAR0-4), 0 to 6 hours (TOTPAR0-6), and 0 to 8 (TOTPAR0-8) post dose.
Time frame: O to 2, 0 to 4, 0 to 6 and 0-8 hours.
Time to a ≥1-Point Reduction in Numeric Pain Rating Scale (T1PMPR)
Time from study drug administration to a ≥1-point reduction in pain intensity on the 0-10 NPRS, derived mathematically from scheduled post-dose pain assessments.
Time frame: 0 to 8 hours post-dose
Time to a ≥2-Point Reduction in Numeric Pain Rating Scale (T2PMPR)
Time from study drug administration to a ≥2-point reduction in pain intensity on the 0-10 NPRS, derived mathematically from scheduled post-dose pain assessments.
Time frame: 0 to 8 hours post-dose
Time to first use of rescue medication
Rescue medication time for SRP-001 compared with placebo
Time frame: 0 - 6, 0-8, 0-24 hours post dose.
Total rescue medication consumption
Total rescue medication consumption for SRP-001 compared with placebo
Time frame: 0 - 6, 0-8, 0-24 hours post dose.
Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)
Safety as assessed by number of participants with AEs and SAEs for SRP-001 compared with placebo and relationship to study medication
Time frame: Day 1 through Follow-up Visit (Day 8 ± 2 days)
Pain intensity difference (PID) using the 11-point numeric pain rating scale (NPRS)
Pain intensity difference (PID) Scale is -10 to 10 (higher is better)
Time frame: 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, and 8 hours post-dose
Patient's global evaluation of study drug using a 5 point categorical scale
Patient's global evaluation of study drug immediately before the first dose of rescue medication, or at early termination (whichever occurs first) using 5 point scale where 0=poor o 4=excellent
Time frame: Up to 6 hours post dose
Number of participants with clinically significant abnormalities in laboratory abnormalities
Number of participants with laboratory values judged clinically significant by the investigator in the following panels: Liver function tests (ALT, AST, bilirubin, alkaline phosphatase) Renal function tests (creatinine, BUN) Hematology parameters (CBC with differential)
Time frame: Screening, Day 1 pre-surgery and follow-up visit, Day 8 ± 2
Maximum Observed Plasma Concentration (CMax) of SRP-001
CMax of SRP001 following a single 2,000mg oral dose, obtained directly from the plasma concentration data
Time frame: Pre-dose and 15, 30, 45 min and 1, 1.5, 2, 3, 4, 6, 8, 10, 12 h post-dose
Time to maximum observed plasma concentration (Tmax) of SRP-001
Tmax of SRP-001 following a single 2,000mg oral dose, obtained directly from the plasma concentration-time data
Time frame: Pre-dose and 15, 30, 45 min and 1, 1.5, 2, 3, 4, 6, 8, 10, 12 h post-dose
Area under the plasma concentration-time curve from 0-12 hours (AUC0-12) of SRP-001
AUC0-12 of SRP-001 following a single 2,000mg oral dose.
Time frame: Pre-dose through 12 hours post-dose
Area under the plasma concentration time curve from time 0 to the last measurable concentration (AUC0-t) of SRP-001
AUC0-t of SRP001 following a single 2,000mg oral dose
Time frame: Pre-dose and 15, 30, 45 min and 1, 1.5, 2, 3, 4, 6, 8, 10, 12 h post-dose
Area under the plasma concentration time curve from time 0 extrapolated to infinity (AUC0-inf) of SRP-001
AUC0-inf of SRP-001 following a single 2,000mg oral dose
Time frame: Pre-dose and 15, 30, 45 min and 1, 1.5, 2, 3, 4, 6, 8, 10, 12 h post-dose
Terminal elimination half life (t 1/2) of SRP-001
t 1/2 of SRP-001 following a single 2,000mg oral dose
Time frame: Pre-dose and 15, 30, 45 min and 1, 1.5, 2, 3, 4, 6, 8, 10, 12 h post-dose
Apparent oral clearance (CL/F) of SRP-001
CL/F of SRP-001 following a single 2,000mg oral dose
Time frame: Pre-dose and 15, 30, 45 min and 1, 1.5, 2, 3, 4, 6, 8, 10, 12 h post-dose
Apparent volume of distribution during the terminal phase (Vx/F) of SRP-001
Vz/F of SRP-001 following a single 2,000mg oral dose
Time frame: Pre-dose and 15, 30, 45 min and 1, 1.5, 2, 3, 4, 6, 8, 10, 12 h post-dose
Pain relief Difference (PR) using the 11-point numeric pain rating scale (NPRS)
Pain relief difference (PR)
Time frame: Pre-dose and 15, 30, 45 min and 1, 1.5, 2, 3, 4, 6, 8, 10, 12 h post-dose
Time to first perceptible relief and time to confirmed perceptible pain relief
TPPR and TCPR via stopwatch 1
Time frame: 0-4.5 hours post dose
Time to meaningful relief
TMPR via Stopwatch 2
Time frame: 0-4.5 hours post dose
Time to complete pain relief
TCOMPR, NPRS = 0
Time frame: 0 to 8 hours post-dose
Plan to share: No
Start is estimated for Nov 2026; primary completion for Feb 2027, 2 months later.
Of 40 phase 2 interventional studies under Acute Pain, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 23. This study's planned 2 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
South Rampart Pharma, Inc.